Open Access

ARTICLE

How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer

Robert Dreicer

Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio, USA
Address correspondence to Dr. Robert Dreicer, Department of Solid Tumor Oncology, Cleveland Clinic, 9500 Euclid Avenue, R35, Cleveland, OH 44195 USA

Canadian Journal of Urology 2014, 21(Suppl.2), 93-97.

Abstract

instruction: Introduction: Rapid progress has recently been made in understanding the biology of advanced prostate cancer. This has translated into the development of a number of novel agents to treat metastatic castration-resistant prostate cancer (mCRPC).
instruction: Materials and methods: The relevant literature was retrieved from a search of MEDLINE with appropriate keywords.
instruction: Results: Therapeutic approaches to mCRPC include chemotherapy, hormonal manipulation, immunotherapy and radioisotope therapy. Docetaxel and cabazitaxel are cytotoxic agents which have demonstrated a modest impact on survival. Hormonal manipulation with abiraterone and enzalutamide have also been reported to be beneficial in mCRPC. The radioisotope radium-223 utilizes a novel approach in treating mCRPC and was recently described in a positive phase III trial. Finally, sipuleucel-T is an immunotherapy that has a demonstrated overall survival benefit in mCRPC.
instruction: Conclusions: A number of phase III trials have been published that describe agents which are beneficial in treating mCRPC. Future research will focus on sequencing these agents in a clinically rational and economically viable manner.

---

Keywords

---